Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer

Tumours arising in BRCA1 mutation carriers and sporadic basal-like breast carcinomas have similar phenotypic, immunohistochemical and clinical characteristics. SOX2 is an embryonic transcription factor located at chromosome 3q, a region frequently gained in sporadic basal-like and BRCA1 germline mut...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2007-04, Vol.20 (4), p.474-481
Main Authors: Rodriguez-Pinilla, Socorro M, Sarrio, David, Moreno-Bueno, Gema, Rodriguez-Gil, Yolanda, Martinez, Miguel A, Hernandez, Lucia, Hardisson, David, Reis-Filho, Jorge S, Palacios, Jose
Format: Article
Language:English
Subjects:
basal-like phenotype
Biomarkers, Tumor - metabolism
Breast cancer
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Female
HMGB Proteins - metabolism
Humans
Immunohistochemistry
Laboratory Medicine
Medicine
Medicine & Public Health
Neoplasms, Basal Cell - metabolism
Neoplasms, Basal Cell - pathology
node-negative breast carcinomas
original-article
Pathology
Phenotype
Sex-Determining Region Y Protein - metabolism
SOX2
SOXB1 Transcription Factors
Tissue Array Analysis
tissue microarray
Transcription Factors - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumours arising in BRCA1 mutation carriers and sporadic basal-like breast carcinomas have similar phenotypic, immunohistochemical and clinical characteristics. SOX2 is an embryonic transcription factor located at chromosome 3q, a region frequently gained in sporadic basal-like and BRCA1 germline mutated tumours. The aim of the study was to establish whether sox2 expression was related to basal-like sporadic breast tumours. Two hundred and twenty-six sporadic node-negative invasive breast carcinomas were immunohistochemically analysed for oestrogen receptor (ER), progesterone receptor (PR), CK5/6, EGFR, vimentin, HER2, ki67, p53 and sox2 using tissue microarrays. Tumours were considered to have basal-like phenotype if they were ER/HER2-negative and CK5/6 and/or EGFR-positive. Thirty cases of this series (13.7%) displayed a basal-like phenotype. Sox2 expression was observed in 16.7% of cases and was significantly more frequently expressed in basal-like breast carcinomas (43.3% in basal-like, 10.6% in luminal and 13.3% in HER2+ tumours, P
ISSN:0893-3952
1530-0285
DOI:10.1038/modpathol.3800760